Products & Solutions

Nuclear Medicine

PET/CT Radiopharmaceutical Drugs

01 18F‑FDG

Maps glucose metabolism to help find and monitor cancers; also used in heart viability and certain brain conditions for functional assessment.

Image

02 18F‑PSMA

Targets PSMA to detect prostate cancer at staging and recurrence, delivering high‑contrast pelvic imaging.

Image

03 18F‑Flutemetamol (FMM)

A radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.

Image

04 Drugs OEM & ODM

Comprehensive OEM and ODM for radiopharmaceuticals: formulation, technology transfer, cGRPP documentation, QC release, compliant packaging, and distribution.

Image

05 New Pipeline & Research Products

Advancing pipeline radiotracers for oncology and neurology, collaborative research, early access, quantification, guideline-aligned protocols.

Image
Image

About

HKCL specialize in developing and producing high-quality Positron Emission Tomography (PET) radiopharmaceuticals, such as Fluorodeoxyglucose (18F-FDG), Prostate-Specific Membrane Antigen (18F-PSMA), and F-Flutemetamol (18F-FMM).

Links

Contact

G12 & 13, Biotech Centre 2, No.11 Science Park West Avenue, Hong Kong Science Park, Shatin, N. T.

(852) 2332 0989

(852) 2332 0979

Hong Kong Cyclotron Laboratories Limited © 2025. All Right Reserved.